Clinical trials rules refined by MHRA in preparation of post Brexit
In a recent statement the MHRA has clarified how the UK’s clinical trials rules will function in partnership with the EU after Britain leaves March next year. “As part of exit negotiations, MHRA is working to ensure that we continue to have the best possible environment in which to support clinical trials,” the agency said.